Go online to PeerView.com/CMX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in sickle cell disease discuss current and future disease management strategies, including recent safety, efficacy, and tolerability data for currently approved and emerging therapies. Upon completion of this CE activity, participants will be able to: Discuss the disease burden, etiopathogenesis, complications, and unmet needs associated with SCD, Appraise recent safety, efficacy, and tolerability data associated with currently approved and emerging therapies for SCD including anti-adhesion agents, antisickling agents, and pyruvate kinase-R (PKR) activators among others, Develop treatment plans to prevent and/or reduce veno-occlusive crises and end-organ damage in patients with SCD, Implement collaborative strategies and shared decision-making practices to ensure patient engagement in treatment decisions and management of therapy-related adverse events.